These results showed that HER2 status in patients with AFP-GC should be examined to investigate its unique characteristics from clinical, pathological, and molecular aspects and improve the prognosis of patients with AFP-GC by providing optional treatments for molecular targets. The gene discussed is ERBB2; the disease is gastric cancer.